Can a cheaper drug keep leukemia in check after stronger treatment?
NCT ID NCT01316250
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study looked at whether people with chronic myeloid leukemia (CML) who achieved a good response after 12 months on nilotinib could switch to imatinib and keep that response. 13 newly diagnosed adults took part. The goal was to see if imatinib could maintain the remission at a lower cost and with fewer diet restrictions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
American University of Beirut Medical Center
Beirut, Lebanon
Conditions
Explore the condition pages connected to this study.